A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are managed.

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for meds like Ozempic and Zepbound has decreased.

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Nurx, a leading telehealth platform specializing in women's health, is excited to announce an integration agreement with ...